As constitute 10%-11% of glial tumors and it is known through the new classification that the genetic alterations that differentiate grade II-III astrocytic tumors from oligodendrogliomas are p53 and alpha thalassemia/mental retardation syndrome (ATRX) mutations (4). This evidence concerns the gene TP53 and glioma.